| Name of the Instrument/Tool | Psoriatic Arthritis Switch Quality Assessment tool (PASQAL) |
| First Description |
Laires PA, Carrilho M, Tavares-Costa J, Lucas P, Machado P, Cunha-Miranda L, Pimentel-Santos F, Santos H, Vieira-Sousa E, Santos MJ. Development and validation of psoriatic arthritis switch quality assessment tool (PASQAL) - an outcomes measurement tool to assess the quality of biologic switch decisions in psoriatic arthritis. Acta Reumatol Port. 2020 Jan-Mar;45(1):46-57. English. PMID: 32578579. |
| Year | 2020 |
| Domains | |
| Concept of constructs | Biologic switch assessment |
| Population/Disease | Disease specific |
| Originally developed for | Psoriatic Arthritis (PsA) |
| Other rheumatic diseases where can be applied (only if validated) |
--- |
| Additional population with no rheumatic diseases |
No |
| Language: Originally published in | Portuguese |
| Available in Language | English |
| REFERENCE IDENTIFICATION | |
| Author/s | Laires PA, Carrilho M, Tavares-Costa J, Lucas P, Machado P, Cunha-Miranda L, Pimentel-Santos F, Santos H, Vieira-Sousa E, Santos MJ. |
| Title | Development and validation of psoriatic arthritis switch quality assessment tool (PASQAL) - an outcomes measurement tool to assess the quality of biologic switch decisions in psoriatic arthritis. |
| Journal | Acta Reumatol Port. |
| Year | 2020 |
| Vol | 45 |
| Num | 1 |
| Pages | 46-57 |
| Country | Portugal |
| Language | English |
| Other references of interest | |
| No other References. | |
| Instrument/Tool Translations References | |
| No other References. | |
| DEVELOPER CONTACT INFORMATION | |
| Correspondence to | Pedro A. Laires |
| pedro.laires@ensp.unl.pt | |
| Address | Centro de Investigação em Saúde Pública Escola Nacional de Saúde Pública Universidade NOVA de Lisboa |
| Website | --- |
| Available | --- |
| Links | --- |
| DESCRIPTION OF THE INSTRUMENT | |
| Type Of Measure | Composite Index |
| Brief Description |
PASQAL is a measure that aims to evaluate the biologic switch in PsA patients and consists of 6 domains (joint disease activity, dactylitis, enthesis, physical function, quality of life, and skin and nail manifestations), respective instruments and thresholds. pPASQAL: DAPSA, dactylitis count, SPARCC, HAQ-DI, EQ-5D, skinPGA. axPASQAL: ASDAS, dactylitis count, MASES, BASFI, EQ-5D, skinPGA. |
| Number of Items | 6, different for pPASQAL and axPASQAL |
| Range | --- |
| Responses options/scale |
No |
| Developed for | --- |
| PRACTICAL APPLICATION | |
| Method of administration | Physician |
| Recommendations to score |
PASQAL is an outcome measure that address the quality of treatment decisions in PsA regarding the switch of biologic therapies in clinical practice. The classification of the biologic switch was divided into three quality levels: “Good”, based on treat-to-target thresholds; “Moderate”, based on improvement from baseline; and the remaining as “Insufficient”. Regarding overall switch quality, a “Good” biologic switch was defined when comprising most of the domains with “Good” outcome and up to 1 or 2 domains with a “Moderate” outcome, out of 5 or 6 evaluated domains, respectively. A “Moderate” switch outcome was defined when comprising most of the domains with “Good” or “Moderate” outcomes and up to 1 or 2 domains with an “Insufficient” outcome, out of 5 or 6 evaluated domains, respectively. |
| Score Interpretation | --- |
| Cut-off points | --- |
| Cut-off points applied to | --- |
| Smallest detectable change if described | --- |
| Smallest detectable change applied to | --- |
| Completion time by the patient | - minutes |
| Scoring time by the assessor | - minutes |
| Training to score | Not necessary |
| Strengths | Useful in clinical practice & research |
| Limitations | --- |
| OTHER COMMENTS | |
| Other Comments |
PASQAL needs to be tested in a larger sample to further analyze its performance, usability and feasibility. |